0.00Open0.00Pre Close0 Volume0 Open Interest61.00Strike Price0.00Turnover0.00%IV-13.29%PremiumNov 1, 2024Expiry Date9.35Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma7.37Leverage Ratio--Theta--Rho--Eff Leverage--Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet